A board-certified medical oncologist, Daniel M. Halperin, MD, specializes in the treatment of neuroendocrine tumors (NETs). Dr. Halperin is a physician on the gastrointestinal oncology team at Winship Cancer Institute of Emory University.
Dr. Halperin is an associate professor and serves as vice chair for clinical affairs in the Department of Hematology and Medical Oncology at Emory University School of Meecine. As vice chair of clinical affairs, he works with the department chair and other leaders to plan, communicate and execute Winship strategies and organizational goals in the clinical arena, and to support and direct the performance of physician faculty members in the department.
Dr. Halperin received his medical degree from Weill Cornell Medical College in New York City, New York. He completed his internal medicine residency at Brigham and Women's Hospital in Boston, Massachusetts and his medical oncology training at University of Texas MD Anderson Cancer Center in Houston, Texas.
Titles & Roles
Associate Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology
Emory University School of Medicine
Education & Training
Education
Fellowship, Hematology/Oncology, 2015
University of Texas M. D. Anderson Cancer Center, Houston, TX
Residency, Internal Medicine, 2012
Brigham and Women's Hospital
Internship, Internal Medicine, 2010
Brigham and Women's Hospital
Medical Education, MD, 2009
Weill Cornell Medical College
Board Certifications
Medical Oncology
American Board of Internal Medicine, 2015
Internal Medicine
American Board of Internal Medicine, 2013
Professional Memberships
Dr. Halperin serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society.
Research
As a clinical investigator, Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with neuroendocrine tumors (NETs), which are tumors that develop from a diffuse network of neuroendocrine cells that make and release hormones into the bloodstream to control essential bodily functions. He has played a leading role in clinical trials of immunotherapy and radioligands for patients with NETs. He also collaborates with laboratory and population scientists to deepen our understanding of the molecular basis and clinical presentation of neuroendocrine tumors.
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care.
Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to
all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations
behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful
for our patients, please click here.